Pharsight

Oraverse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6872390 SEPTODONT HOLDING Local anesthetic methods and kits
May, 2021

(2 years ago)

US6764678 SEPTODONT HOLDING Local anesthetic methods and kits
May, 2021

(2 years ago)

US7575757 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Jul, 2023

(8 months ago)

US7229630 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Jul, 2023

(8 months ago)

US7569230 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Oct, 2023

(6 months ago)

Oraverse is owned by Septodont Holding.

Oraverse contains Phentolamine Mesylate.

Oraverse has a total of 5 drug patents out of which 5 drug patents have expired.

Expired drug patents of Oraverse are:

  • US6872390
  • US6764678
  • US7575757
  • US7229630
  • US7569230

Oraverse was authorised for market use on 09 May, 2008.

Oraverse is available in injectable;injection dosage forms.

Oraverse can be used as a method of reversing soft-tissue anesthesia i.e. anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic.

The generics of Oraverse are possible to be released after 17 October, 2023.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Mar 18, 2019

Drugs and Companies using PHENTOLAMINE MESYLATE ingredient

Market Authorisation Date: 09 May, 2008

Treatment: A method of reversing soft-tissue anesthesia i.e. anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic

Dosage: INJECTABLE;INJECTION

More Information on Dosage

ORAVERSE family patents

Family Patents